SG11201510181YA - Compositions and methods using capsids resistant to hydrolases - Google Patents

Compositions and methods using capsids resistant to hydrolases

Info

Publication number
SG11201510181YA
SG11201510181YA SG11201510181YA SG11201510181YA SG11201510181YA SG 11201510181Y A SG11201510181Y A SG 11201510181YA SG 11201510181Y A SG11201510181Y A SG 11201510181YA SG 11201510181Y A SG11201510181Y A SG 11201510181YA SG 11201510181Y A SG11201510181Y A SG 11201510181YA
Authority
SG
Singapore
Prior art keywords
hydrolases
compositions
methods
capsids
resistant
Prior art date
Application number
SG11201510181YA
Inventor
Juan Pedro Humberto Arhancet
Juan P Arhancet
Kimberly Delaney
Kathleen B Hall
Neena Summers
Edward Oates
Original Assignee
Apse Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apse Llc filed Critical Apse Llc
Publication of SG11201510181YA publication Critical patent/SG11201510181YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8616—Special methods for targeting systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
SG11201510181YA 2013-06-19 2014-06-05 Compositions and methods using capsids resistant to hydrolases SG11201510181YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361836833P 2013-06-19 2013-06-19
US201361838736P 2013-06-24 2013-06-24
US201361857965P 2013-07-24 2013-07-24
PCT/US2014/041111 WO2014204667A1 (en) 2013-06-19 2014-06-05 Compositions and methods using capsids resistant to hydrolases

Publications (1)

Publication Number Publication Date
SG11201510181YA true SG11201510181YA (en) 2016-01-28

Family

ID=52105110

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201805197VA SG10201805197VA (en) 2013-06-19 2014-06-05 Compositions and methods using capsids resistant to hydrolases
SG11201510181YA SG11201510181YA (en) 2013-06-19 2014-06-05 Compositions and methods using capsids resistant to hydrolases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201805197VA SG10201805197VA (en) 2013-06-19 2014-06-05 Compositions and methods using capsids resistant to hydrolases

Country Status (15)

Country Link
US (2) US9822361B2 (en)
EP (3) EP3010494B1 (en)
JP (1) JP6636418B2 (en)
AU (1) AU2014281061B2 (en)
BR (1) BR112015029559A2 (en)
CA (1) CA2912131C (en)
CY (1) CY1124583T1 (en)
DK (1) DK3222274T3 (en)
ES (1) ES2847151T3 (en)
HU (1) HUE053033T2 (en)
IL (1) IL242487B (en)
MX (2) MX364809B (en)
PL (1) PL3222274T3 (en)
SG (2) SG10201805197VA (en)
WO (1) WO2014204667A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130167267A1 (en) * 2011-12-21 2013-06-27 Apse, Llc Processes using vlps with capsids resistant to hydrolases
AU2014281061B2 (en) 2013-06-19 2019-07-18 Rnaissance Ag Llc Compositions and methods using capsids resistant to hydrolases
US9932563B2 (en) * 2013-09-11 2018-04-03 Georgia Tech Research Corporation Compositions and methods for inhibiting gene expressions
JP2018515079A (en) * 2015-05-12 2018-06-14 アプス， エルエルシー In vivo generation of long double-stranded RNA using VLP
EP3356531A4 (en) * 2015-10-01 2019-05-29 Apse Llc Methods and compositions comprising apse knots
CN109196102B (en) 2016-03-15 2022-04-26 阿普斯公司 Methods and compositions for increasing double-stranded RNA production
CA3037192A1 (en) 2016-11-07 2018-05-11 nanoSUR LLC Post-transcriptionally chemically modified double strand rnas
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
AR126939A1 (en) 2021-08-31 2023-11-29 nanoSUR LLC HIGH MOLECULAR WEIGHT MODIFIED dsRNA COMPOSITIONS RELATED TO BIOCIDES

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443969A (en) 1992-10-29 1995-08-22 Rutgers University RNA packaging system
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US6232287B1 (en) * 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
PT2796553T (en) * 2000-03-30 2019-09-27 Massachusetts Inst Technology Rna sequence-specific mediators of rna interference
CH695778A5 (en) * 2000-11-29 2006-08-31 Hoffmann La Roche Inhibition of transcription of a target gene in a cell or in tissues.
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
JP4790984B2 (en) 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド Alphavirus replicon vector system
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
WO2005001039A2 (en) * 2003-05-29 2005-01-06 Creighton University Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
EP3388521A1 (en) 2004-02-27 2018-10-17 Dow AgroSciences LLC High efficiency peptide production in plant cells
GR20060100496A (en) * 2006-09-01 2008-04-15 Παρθενιος Μπουλικας LIPOSOMALLY ENCAPSULATED HYBRID ADENOVIRUS-SEMLIKI FOREST VIRUS (SFV) VECTORS CARRYING RNAi CONSTRUCTS AND THERAPEUTIC GENES FOR USE AGAINST CANCER TARGETS AND OTHER DISEASES.
US20080171361A1 (en) * 2007-01-11 2008-07-17 The Board Of Regents For Oklahoma State University CAP-Independent Translational Enhancer for Protein Synthesis in Wheat Germ Extract and Transgenic Cereals
CN101784655A (en) 2007-04-27 2010-07-21 菲尼克斯股份有限公司 Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
US20110111481A1 (en) * 2007-06-29 2011-05-12 Chiang Li ENABLING THE USE OF LONG dsRNA FOR GENE TARGETING IN MAMMALIAN AND OTHER SELECTED ANIMAL CELLS
EP2085479A1 (en) 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast
WO2009120883A2 (en) 2008-03-26 2009-10-01 Life Technologies Corporation Virus-like particle mediated cellular delivery
US8324149B2 (en) 2008-11-18 2012-12-04 The Board Of Trustees Of The Leland Stanford Junior University Encapsidation of heterologous entities into virus-like particles
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle
US8906863B2 (en) * 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
EP2443241A1 (en) * 2009-06-15 2012-04-25 Plant Bioscience Limited Production of viral capsids
ES2809679T3 (en) 2010-03-08 2021-03-05 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
US20130017210A1 (en) 2010-03-17 2013-01-17 Stc.Unm Display of antibody fragments on virus-like particles of rna bacteriophages
US20130245102A1 (en) * 2010-10-12 2013-09-19 Research Foundation Of The City University Of New York Novel dna templates for small rna production in mammalian cells
US20130224828A1 (en) * 2010-11-01 2013-08-29 Qapsule Technologies, Inc. RNA-Directed Packaging of Enzymes Within Protein Particles
JP2013018754A (en) * 2011-07-13 2013-01-31 Univ Of Tokushima Therapeutic agent for treating malignant pleural mesothelioma
JP6137484B2 (en) * 2011-11-02 2017-05-31 公立大学法人大阪市立大学 Double-stranded nucleic acid molecule for gene expression suppression
US20130167267A1 (en) * 2011-12-21 2013-06-27 Apse, Llc Processes using vlps with capsids resistant to hydrolases
AU2014281061B2 (en) 2013-06-19 2019-07-18 Rnaissance Ag Llc Compositions and methods using capsids resistant to hydrolases
US9932563B2 (en) * 2013-09-11 2018-04-03 Georgia Tech Research Corporation Compositions and methods for inhibiting gene expressions

Also Published As

Publication number Publication date
MX2015017593A (en) 2016-04-15
PL3222274T3 (en) 2021-07-19
EP3789017A1 (en) 2021-03-10
CA2912131A1 (en) 2014-12-24
DK3222274T3 (en) 2020-11-02
EP3222274A1 (en) 2017-09-27
EP3010494A4 (en) 2017-06-07
BR112015029559A2 (en) 2017-12-12
MX2019005298A (en) 2019-08-12
CA2912131C (en) 2020-07-07
CY1124583T1 (en) 2022-03-24
JP6636418B2 (en) 2020-01-29
HUE053033T2 (en) 2021-06-28
SG10201805197VA (en) 2018-07-30
EP3222274B1 (en) 2020-10-21
US10428329B2 (en) 2019-10-01
IL242487B (en) 2020-05-31
WO2014204667A1 (en) 2014-12-24
ES2847151T3 (en) 2021-08-02
JP2016521992A (en) 2016-07-28
US20180030445A1 (en) 2018-02-01
AU2014281061A1 (en) 2015-11-26
US20160177299A1 (en) 2016-06-23
MX364809B (en) 2019-05-07
EP3010494A1 (en) 2016-04-27
EP3010494B1 (en) 2018-08-15
US9822361B2 (en) 2017-11-21
AU2014281061B2 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
IL273205A (en) Compositions and methods
IL269461B (en) Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
HK1218837A1 (en) Compositions and methods
HK1218560A1 (en) Compositions and methods
HK1225754A1 (en) Methods and compositions for genome engineering
GB2527241B (en) Compositions and methods
AP2016009060A0 (en) Compositions and methods related to isolated endophytes
IL286759A (en) Therapeutic methods and compositions
GB201308072D0 (en) Compositions and methods
EP2964235A4 (en) Antimicrobial-antibiofilm compositions and methods of use thereof
IL242487B (en) Compositions and methods using capsids resistant to hydrolases
EP2958523A4 (en) Cartilage mosaic compositions and methods
GB201322094D0 (en) Methods and compositions relating to alzheimers disease
GB201305813D0 (en) Compositions and methods
SG11201505891VA (en) Catalyst compositions and methods of making and using same
EP2961386A4 (en) Mirna profiling compositions and methods of use
GB201315350D0 (en) Methods and compositions
EP2964610A4 (en) Vinylsulfone-based 18f-labeling compositions and methods and uses thereof
GB201315347D0 (en) Methods and compositions
EP2981334A4 (en) Compositions and methods for inhibiting viral activity
EP2870238A4 (en) Compositions and methods related to viral vaccines
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
GB201319255D0 (en) Therapeutic compositions and methods
EP2841164A4 (en) Dermal-appropriate compositions and methods of use